DOI: https://doi.org/10.22141/2224-0721.6.54.2013.84628

Hormonal and Biochemical Characteristic of Patients with Ischemic Heart Disease and Adult Growth Hormone Deficiency

M.Yu. Shakirova, Yu.M. Urmanova, A.B. Shek, A.R. Madmusaeva

Abstract


In this article the authors analyzed the results of examination of 21 adult patients with ischemic heart disease against adult growth hormone deficiency. The decreasing of mean levels of growth hormone, LH in men and FSH in women in the first group of patients, and in the second group — decrease of mean levels of growth hormone, IGF-1, LH in men and FSH in women indicates the hypopituitarism in both groups of patients, as well as trend to the development of secondary hypogonadism in men. In patients of first and second groups we found increasing of the levels of total cholesterol, VLDL, atherogenic index (p < 0.05), more significant rise of mean levels of triglycerides (p < 0.01), at that more significant disorders of lipid and carbohydrate metabolism were detected in patients of second group. Average levels of LDL, HDL, conjugated bilirubin, urea, blood creatinine and fasting glycemia were also increased.

Keywords


adult growth hormone deficiency; ischemic heart disease; obesity

References


Дедов И.И., Петеркова В.А., Безлепкина О.Б., Волеводз Н.Н. Национальный консенсус «Применение гормона роста у взрослых и детей». III Всероссийская научно-практическая конференция «Актуальные проблемы нейроэндокринологии». — Москва, 6–7 октября 2003 г.

Дедов И.И., Тюльпаков А.Н., Петеркова В.А. Соматотропная недостаточность. — М., 1998. — 250 с.

Щукина. В.Н. Роль соматотропной недостаточности в генезе ИБС у больных с сахарным диабетом 2-го типа: Автореф. дис… канд. мед. наук. — М., 2006. — 28 с.

Abdu T.A., Neary R., Elhadd T.A. et al. Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities // Clinical Endocrinology. — 2001. — Vol. 55. — P. 209-216.

Abs R., Feldt-Rasmussen U., Mattsson A.F., Monson J.P. Determinants of cardiovascular risk in 2589 hypopituitary growth hormone-deficient adults // European Journal of Endocrinology. — 2006. — Vol. 155. — P. 79-90.

Bates A.S., Van’t Hoff W., Jones P.J., Clayton R.N. The effect of hypopituitarism on life expectancy // J. Clin. Endocrinol. Metab. — 1996. — Vol. 81. — P. 1169-1172.

Bertella L., Mori I., Grugni G. et al. Quality of life and psychological well-being in GH-treated, adult PWS patients: a longitudinal study // J. Intellect. Disabil. Res. — 2007. — Vol. 51(Pt 4). — P. 302-311.

Bengtsson B.-А. Untreated growth hormone deficiency explains premature mortality in patients with hypopituitarism // Growth Hormone and IGF Research. — 1998. — Vol. 8. — P. 480-485.

Beshyah S.A., Johnston D. Cardiovascular disease and risk factors in adults with hypopituitarism // Clinical Endocrinology. — 1999. — Vol. 50. — P. 1-15.

Boschetti M., Goglia U., Teti C. Replacement therapy and cardiovascular diseases // J. Endocrinol. Invest. — 2008. — Vol. 31(9 Suppl). — P. 85-90.

Cannavо S., Marini F., Curtо L., Torre M.L. High prevalence of coronary calcifications and increased risk for coronary heart disease in adults with growth hormone deficiency // J. Endocrinol. Invest. — 2011. — Vol. 34(1). — P. 32-37.

Franco C., Bengtsson B.A., Johannsson G. The GH/IGF-1 axis in obesity: physiological and pathological aspects // Metab. Syndr. Relat. Disord. — 2006. — Vol. 4(1). — P. 51-56.

Follin C., Thilеn U., Osterberg K. et al. Cardiovascular risk, cardiac function, physical activity, and quality of life with and without long-term growth hormone therapy in adult survivors of childhood acute lymphoblastic leukemia // J. Clin. Endocrinol. Metab. — 2010. — Vol. 95(8). — P. 3726-3735.

Johansson J.-O., Landin K., Tengborn L. High fibrinogen and plasminogen activator inhibitor activity in growth hormone deficient adults // Arteriosclerosis and Thrombosis. — 1994. — Vol. 14. — P. 434-437.

Monson J.P., Jоnsson P., Koltowska-Hаggstrоm M., Kourides I. Growth hormone replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy // Clinical Endocrinology. — 2007.

Murray R.D., Shalet S.M. The use of self-rating questionnaires as a quantitative measure of quality of life in adult growth hormone deficiency // J. Endocrinol. Invest. — 1999. — Vol. 22(5 Suppl). — P. 118-126.

Murray R.D., Wieringa G., Lawrance J.A. Partial growth hormone deficiency is associated with an adverse cardiovascular risk profile and increased carotid intima-medial thickness // Clin. Endocrinol. (Oxf). — 2010. — Vol. 73(4). — P. 508-515.

Savastano S., Di Somma C., Belfiore A., Guida B. Growth hormone status in morbidly obese subjects and correlation with body composition // J. Endocrinol. Invest. — 2006. — Vol. 29(6). — P. 536-543.

Verhelst J., Abs R. Cardiovascular risk factors in hypopituitary GH-deficient adults // Eur. J. Endocrinol. — 2009. — Vol. 161(Suppl 1). — S41-49.

Ukropec J., Penesovа A., Skopkovа M. et al. Adipokine protein expression pattern in growth hormone deficiency predisposes to the increased fat cell size and the whole body metabolic derangements // J. Clin. Endocrinol. Metab. — 2008. — Vol. 93(6). — P. 2255-2262.

Ur E., Serri O., Legg K. et al. Canadian guidelines for the management of adult growth hormone deficiency // Clin. Invest. Med. — 2006. — Vol. 29(2). — P. 83-90.

Wallymahmed M.E., Foy P., MacFarlane I.A. The quality of life of adults with growth hormone deficiency: Comparison with diabetic patients and control subjects // Clin. Endocrinol. (Oxf). — 1999. — Vol. 51. — P. 333-338.




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2018

 

   Seo анализ сайта